Two successful and dedicated ophthalmic companies – Labtician Ophthalmics, Inc. in Canada, and Théa Laboratoires of France – have joined forces to offer quality ophthalmic pharmaceutical products.
Labtician Ophthalmics, Inc. created in 1959, provides specialty ophthalmic products and has developed an outstanding portfolio with a reputation for quality and customer service.
Théa Laboratoires, created in 1994, is Europe’s leading independent ophthalmic company and has developed a large and complete ophthalmic pharmaceutical portfolio.
Labtician Théa will offer high quality ophthalmic products to ophthalmologists, optometrists and their patients. Labtician Théa will specialize in Dry Eye and Eye Lid Hygiene, with preservative free products dedicated to improving eye health.
Labtician Théa will promote to health professionals through a highly trained and professional sales team dedicated to ophthalmology and optometry.
Contact:
Address: 2140 Winston Park Dr, Oakville, ON L6H 5V5, Canada
Tel.: +1 905 829 0055
Website: http://www.labticianthea.com/
Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific…
Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the…
In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review…
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific steps that have been taken in the journey towards a National Pharmacare program in…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising…
See our Cookie Privacy Policy Here
